BPC-157 + TB-500

What BPC-157 + TB-500 is

BPC-157 + TB-500 is a pairing of two lab-made peptides. A peptide is a short chain of amino acids, the building blocks of protein. Each one has a large body of animal and cell research on tissue repair. No published study has tested them together, in cells, in animals or in people.

• BPC-157 stands for Body Protection Compound-157. It has 15 amino acids. The chain is copied from a sequence found in human stomach juice.
• TB-500 is a man-made piece of Thymosin Beta-4. That is a natural protein with 43 amino acids that sits inside cells. It holds actin in reserve and helps cells move. Actin is a protein that cells use to keep their shape and to travel.

“The combination” means giving both peptides at once. Researchers are interested in it because the two act in different ways that might fit together.

They use very different signal chains. BPC-157 mainly acts on the nitric oxide (NO) system, on growth factor receptors and on brain chemical pathways. TB-500 mainly works through actin, through a pair of signals called integrin-linked kinase (ILK) and Akt, and by waking up progenitor cells, which are early cells that can turn into other cell types.

The case for looking at them together starts from one idea. Good tissue repair needs many things to happen at once. Cells must be protected. Inflammation must be kept in check. New blood vessels must grow. Cells must move in, and the matrix around them must be rebuilt. Each peptide may help more with some of these steps than with others [1], [8].

How much research there is

No peer-reviewed study has ever given BPC-157 and TB-500 together. The same goes for BPC-157 with whole Thymosin Beta-4. That is true for cell studies, animal studies and human studies.

Every claim in this guide that the two work well together is theory. It is worked out from how each peptide acts alone and from each one’s own animal and cell results. Keep this in mind for everything that follows.

Why scientists look at them together

Four findings from the separate research on each peptide drive the interest.

1. They do not share targets. BPC-157 works mainly through the NO system and a pathway called Src-Caveolin-1-eNOS [2]. TB-500 works by holding actin, turning on ILK and Akt, and holding back NFkappaB, a protein that switches on inflammation [8], [14]. These signal chains are mostly separate. In theory, that makes it less likely that one peptide would work against the other.
2. They have been tested in the same tissues. Each one, on its own, has been studied in models of tendon, muscle, heart, nerve and gut. That hints at shared uses in many tissue types [6], [10].
3. They may act at different stages. Animal and cell data suggest BPC-157 is most active early, when cells need protection and blood vessels are being called in. TB-500 may be more active later, when cells move, progenitor cells wake up and the matrix is rebuilt [1], [9].
4. Reviews group them. A 2024 narrative review in the Yale Journal of Biology and Medicine put BPC-157, TB-500 and GHK-Cu in one group of repair agents that may work side by side. It said they help blood vessels grow, switch on fibroblasts (the cells that build connective tissue), and reshape the matrix around cells by way of integrins. It had no data on using them together [17].

None of this is proof that they boost each other. It is reasoning from mechanisms and nothing more. Nobody has tested whether the two help each other, hurt each other or have no effect on each other when given together.

BPC-157 in brief

BPC-157 is a lab-made peptide of 15 amino acids. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and it weighs about 1,419 Da. Scientists at the University of Zagreb first described it in the early 1990s. More than 100 animal and cell studies on it have been published. For the full picture, see the BPC-157 research guide.

Cell protection and nitric oxide

The best documented action of BPC-157 is cytoprotection. This means keeping the body’s own surface linings and blood vessel linings intact. The idea comes from a model first set out by Robert. The peptide is also very stable in stomach acid. It stayed active in human stomach juice for more than 24 hours [1].

It has an unusual two-way effect on nitric oxide, a gas the body makes to relax blood vessels. The Hsieh group in Taiwan showed that BPC-157 turns on the Src-Cav-1-eNOS pathway. This raised both the gene and the protein for nitric oxide synthase (NOS), the enzyme that makes the gas. The effect depends on the setting. When nitric oxide is too low, the peptide raises it. When there is too much, it lowers it. In both cases it also works against free radicals [2].

A 2025 review went further. It proposed that BPC-157 grows blood vessels through the nitric oxide system and not through the usual VEGF route. VEGF is a growth signal for blood vessels [3].

Growth signals

In tendon fibroblasts, BPC-157 raised the receptor for growth hormone. That may make tissue repair respond more strongly to the body’s own growth hormone [5]. It has other links to growth signals too. VEGF went up at wound sites. The EGF receptor changed. FGF pathways were affected [1].

Gut and brain

BPC-157 acts along the link between the gut and the brain. It protects the gut and also has effects in the central nervous system. It interacts with four brain chemical systems: dopamine, serotonin, GABA and opioids. This sets it apart from peptides that work mainly through cell structure or the cell skeleton [4], [7].

TB-500 in brief

TB-500 is a man-made piece of Thymosin Beta-4, a protein of 43 amino acids. Few peptides inside mammal cells are as plentiful. Scientists first isolated Thymosin Beta-4 from thymus tissue. Nearly every cell type makes it. TB-500 copies the active region of the whole protein. For the full picture, see the TB-500 research guide.

Actin and cell movement

Inside the cell, the main job of Thymosin Beta-4 is to hold actin. It binds single actin units, called G-actin. This controls how the cell’s actin skeleton is built up and taken apart. The result is cell movement, which wound healing and tissue repair depend on. In skin wound models in rats, treatment raised regrowth of the skin surface by 42% at 4 days and by 61% at 7 days, compared with saline [10].

Blood vessels and progenitor cells

Two papers stand out.

• Smart and colleagues (2007) worked with adult mouse hearts. Thymosin Beta-4 woke up resting progenitor cells in the epicardium, the outer layer of the heart. That led to new blood vessels and heart repair [9].
• Bock-Marquette and colleagues (2004) found that it protects the heart. It turned on ILK, which then switched on Akt by adding a phosphate group to it. This helped cells survive [8].

Brain repair

Thymosin Beta-4 has been tested in models of traumatic brain injury. Even when treatment began 6 hours after the injury, the damaged area shrank by 20 to 30%. More new neurons formed, along with more oligodendrocytes (cells that insulate nerve fibers) and more axon growth [11], [12]. A 2018 review proposed it as a candidate treatment for acute stroke. The reasons given were its mix of effects: it restores nerve tissue, grows blood vessels and lowers inflammation [13].

Where the two might fit together

The points below come from published research on each peptide alone. They are ideas from theory, not shown effects. No study has tested whether these actions help each other, block each other or interact at all when both peptides are present.

Stages of tissue repair

Tissue heals in stages. The separate animal and cell data suggest that each peptide may support different ones.

Stage of repair	What BPC-157 does	What TB-500 does
Early protection	Protects surface and vessel linings (Robert’s cytoprotection) [1]	Helps cells survive by turning on ILK and Akt [8]
Keeping inflammation in check	Adjusts the NO system and brain chemicals [2]	Holds back NFkappaB and lowers cytokines [14]
New blood vessels	Grows vessels through NO (Src-Cav-1-eNOS) [2]	Moves epicardial progenitor cells, acts on VEGF-linked pathways [9]
Cell movement	Raises growth factor receptors [5]	Holds and releases actin, moves cells directly [10]
Rebuilding the matrix	Raises growth hormone receptor in fibroblasts [5]	Raises MMP-2, lays down collagen [10]
Waking progenitor cells	Not one of its main actions	Restarts epicardial progenitor cells, moves hair follicle stem cells [9], [16]
Against scarring	Little direct evidence	Its breakdown product Ac-SDKP stops fibroblasts from multiplying, through TGF-beta/Smad [15]

The table shows that each peptide’s evidence lines up with different stages, with some overlap. Nobody knows if these separate effects would add up when both are given.

Two routes to new blood vessels

Healing tissue needs new blood vessels, a process called angiogenesis. The vessels bring oxygen and nutrients to the injury. The two peptides seem to grow vessels in different ways.

• BPC-157 uses the Src-Caveolin-1-eNOS pathway. It adjusts nitric oxide output, which controls how tight vessels are and helps new ones form. The Hsieh group in Taiwan described this as a route that does not depend on VEGF [2], [3].
• TB-500 calls up progenitor cells in the epicardium, moves endothelial cells (the cells lining blood vessels) through actin, and uses VEGF-linked pathways [9].

Since the signal chains differ, in theory both could run at once without fighting over the same targets. But nitric oxide signals and the ILK and Akt pathway may affect each other further down the line. Nobody has looked at that here. Unexpected interactions cannot be ruled out.

Brain and nerve repair

Each peptide has protected or restored nerve tissue in animals and cells. Their methods are not alike.

• BPC-157 protects nerves by acting on the dopamine and serotonin systems, along the gut and brain link. It rebalances brain chemicals. It does not rebuild nerve structure [4], [7].
• TB-500 restores nerve tissue. In the injured brain it grew more blood vessels, new neurons, new oligodendrocytes and longer axons. This is repair of structure plus better blood supply [11], [12], [13].

One approach adjusts brain chemicals and the other rebuilds structure. In theory they could cover different parts of a nerve injury. Whether they would help or get in each other’s way in practice has not been studied.

Tendon, muscle and bone

Both have animal and cell evidence for repair of these tissues, by different means.

• BPC-157 raised growth hormone receptor in tendon fibroblasts [5]. That could make the tissue respond better to the body’s own repair signals. A 2025 systematic review confirmed possible benefits for tendon and muscle repair in several animal models. It also said these results are still largely untested in human trials [6].
• TB-500 moved cells into the injury through actin, laid down more collagen and grew more blood vessels in the repair zone [10].

So one makes receptors more sensitive, and the other brings in cells and builds matrix. These are different steps in repair. A 2025 review in JAAOS Global Research & Reviews listed both among peptides with uses in orthopedics. It had no data on the pair [19].

Inflammation

Each peptide lowered inflammation in animals and cells, through its own pathway.

• BPC-157 acts through the NO system and brain chemicals. Its effect goes both ways to restore balance. It does not simply suppress [2].
• TB-500 holds back NFkappaB and lowers cytokines directly. This was shown in corneal injury and other models [14].

This is one more place where the two might fit together in theory. Their joint effect on inflammation has not been studied.

Safety

Each peptide on its own

Neither one has a full human safety record. The main points from animal and cell research are:

• BPC-157: generally well tolerated at the doses tested, usually 1 to 10 mcg/kg in rats. No organ damage, gene damage or cancer was seen in the models tested. No lethal dose (LD50) has been set [1]. A 2025 pilot study reported that 2 healthy adults tolerated infusions into a vein of up to 20 mg [20].
• TB-500: Thymosin Beta-4 has been tested in people only as an eye drop (RGN-259). The TB-500 research guide covers those trials. The animal studies cited here measured healing. They were not set up as safety studies.

Concerns about the pair

These points apply to using both at once. They are concerns from theory. They are not side effects that anyone has seen.

• Two pushes on blood vessel growth. Both peptides grow blood vessels, by different routes. Nobody knows if turning on several such routes at once adds risk. This matters most where a cancer is present but has not been found.
• Nitric oxide. The two-way effect of BPC-157 on NO could, in theory, interact with the ILK and Akt pathway that TB-500 uses. NO sits downstream in many signal chains. Effects that cannot be predicted cannot be ruled out.
• Overlap on the immune system. Both lowered inflammation. It has not been studied whether doing so by two routes at once could suppress the immune system too much or change immune responses.
• Handling by the body. Nobody knows if giving them together changes how either one is absorbed, spread through the body, broken down or cleared.

Legal status in the US

• Not FDA approved. Neither peptide is approved for medical use by the FDA. The same is true of the EMA in Europe and the MHRA in the UK.
• Banned in sport. The World Anti-Doping Agency (WADA) bans both at all times, in and out of competition. Its Prohibited List names BPC-157 under class S0, non-approved substances. It names Thymosin Beta-4 and its derivatives, TB-500 included, under class S2, which covers peptide hormones, growth factors, related substances and mimetics. For an athlete under WADA testing, using either one, alone or together, is a doping violation.
• No combined product. Nobody has sought regulatory approval for a BPC-157 + TB-500 product in any country.
• Research use. Suppliers label them for laboratory research use only, not for human use.

Limits of the research

The gaps here are large.

1. No studies of the pair. This is the biggest gap. No peer-reviewed research has looked at the two together in cells, animals or people. Every claim that they boost each other is drawn from data on each one alone. They might add up, multiply each other, do nothing extra or work against each other. All four are equally possible.
2. No human trials for muscle, tendon or bone. For both peptides, this evidence comes only from animals and cells. The only human clinical data are for RGN-259, a Thymosin Beta-4 product, in eye care. A 2025 pilot study reported that 2 healthy adults tolerated BPC-157 infusions into a vein of up to 20 mg [20]. That says very little about whether it works or about using the pair.
3. Interactions unknown. Nobody has studied whether the two affect each other as drugs when given together. One example is how the NO system might affect ILK and Akt signals. That has not been explored. Unexpected effects cannot be ruled out.
4. Dose unknown. There is no evidence at all for the right doses of the pair. Even the dose of each one alone is poorly worked out in terms that apply to people.
5. Safety of the pair unknown. Safety data for each one alone come only from animals and cells. The two exceptions are RGN-259 in the eye and the BPC-157 pilot infusion study. The safety of the two together has not been described at all.
6. One lab for BPC-157. More than 80% of published BPC-157 studies come from one group, Sikiric and colleagues at the University of Zagreb. Checks by other labs are growing but still limited [18].
7. Cancer risk. TB-500 helps blood vessels grow. In theory, new vessels could help a tumor grow and spread. Nobody knows if the NO effect of BPC-157 changes that risk. The concern applies to either peptide alone. It matters more when two vessel-growing compounds are used together.
8. Missing negative results. For both peptides, studies that found no effect may be missing from the published record. That can make each one’s evidence look better than it is, and with it any case for the pair.

Each peptide has helped animals heal in its own way. Whether the two do anything more together is a question no study has asked.

References

Selected peer-reviewed references. Studies are cited for the individual peptides — no combination studies exist in the published literature.

1. Sikiric P, Rucman R, Turkovic B, et al. (2020). Stable gastric pentadecapeptide BPC 157, Robert’s stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye’s stress coping response: progress, achievements, and the future. Gut and Liver, 14(2), 153–167. PMID: 31158953
2. Hsieh MJ, Liu HT, Wang CN, et al. (2020). Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports, 10, 17048. PMID: 33051481
3. Sikiric P, et al. (2025). BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide’s Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Pharmaceuticals, 18(4), 576. PMC: PMC12567428
4. Sikiric P, Rucman R, Turkovic B, et al. (2016). Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology, 14(8), 857–865. PMC: PMC5333585
5. Chang CH, Tsai WC, Hsu YH, Pang JH. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 19(11), 19066–19077. PMID: 25415472
6. Vasireddi N, et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 21(4). PMID: 40756949
7. Vukojevic J, Milavic M, Peric M, et al. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research, 17(3), 482–487. PMC: PMC8504390
8. Bock-Marquette I, Saxena A, White MD, et al. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432, 466–472. PMID: 15565145
9. Smart N, Risebro CA, Melville AAD, et al. (2007). Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature, 445, 177–182. DOI: 10.1038/nature05383
10. Malinda KM, Sidhu GS, Mani H, et al. (1999). Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology, 113(3), 364–368. PMID: 10469335
11. Xiong Y, Mahmood A, Zhang Y, et al. (2011). Treatment of traumatic brain injury with thymosin beta4 in rats. Journal of Neurosurgery, 114(1), 102–115. PMC: PMC2962722
12. Xiong Y, Zhang Y, Mahmood A, Meng Y, Qu C, Chopp M. (2012). Neuroprotective and neurorestorative effects of thymosin beta4 treatment initiated 6 hours after traumatic brain injury in rats. Journal of Neurosurgery, 116(5), 1081–1092. PMID: 22324420
13. Morris DC, Zhang ZG, Chopp M. (2018). Thymosin β4 for the treatment of acute stroke: neurorestorative or neuroprotective? Expert Opinion on Biological Therapy, 18(sup1), 149–158. PMID: 30063858. PMC: PMC6481613
14. Sosne G, Szliter EA, Barrett R, et al. (2002). Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Experimental Eye Research, 74(2), 293–299. PMID: 11950239
15. Kleinman HK, Sosne G. (2023). Thymosin β4 and the anti-fibrotic switch. International Immunopharmacology, 115, 109628. PMID: 36580759
16. Philp D, Nguyen M, Bhatt B, et al. (2004). Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB Journal, 18(2), 385–387. PMID: 14657002
17. Cushman CJ, Ibrahim AF, Palacios Rosas ME, et al. (2024). Local and Systemic Peptide Therapies for Soft Tissue Regeneration: A Narrative Review. Yale Journal of Biology and Medicine, 97(3), 399–413. PMID: 39351323
18. McGuire FP, et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. PMC: PMC12446177
19. Rahman OF, et al. (2025). Therapeutic Peptides in Orthopaedics. JAAOS Global Research & Reviews. PMC: PMC12753158
20. Lee E, Burgess K. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine, 31(5), 20–24. PMID: 40131143